SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 518,600 shares, a growth of 287.6% from the April 15th total of 133,800 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) – Stock analysts at Chardan Capital lifted their FY2023 earnings per share estimates for shares of SAB Biotherapeutics in a research note issued on Tuesday, April 18th. Chardan Capital analyst K. Nakae now forecasts that the company will earn ($0.52) per share for the year, up from their […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 138,200 shares, a decline of 30.1% from the March 15th total of 197,800 shares. Currently, 0.4% of the company’s shares are short sold. Based […]
SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Rating) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 8,100 shares, a decrease of 64.9% from the February 28th total of 23,100 shares. Based on an average daily trading volume, of 5,400 shares, the short-interest ratio […]
SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Rating) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 8,100 shares, a drop of 64.9% from the February 28th total of 23,100 shares. Based on an average trading volume of 5,400 shares, the days-to-cover ratio is […]